lactic acid has been researched along with Carcinoma, Pancreatic Ductal in 13 studies
Lactic Acid: A normal intermediate in the fermentation (oxidation, metabolism) of sugar. The concentrated form is used internally to prevent gastrointestinal fermentation. (From Stedman, 26th ed)
2-hydroxypropanoic acid : A 2-hydroxy monocarboxylic acid that is propanoic acid in which one of the alpha-hydrogens is replaced by a hydroxy group.
Carcinoma, Pancreatic Ductal: Carcinoma that arises from the PANCREATIC DUCTS. It accounts for the majority of cancers derived from the PANCREAS.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Resistance to gemcitabine remains a key challenge in the treatment of pancreatic ductal adenocarcinoma (PDAC), necessitating the constant search for effective strategies for a priori prediction of clinical outcome." | 7.88 | Metabolomic prediction of treatment outcome in pancreatic ductal adenocarcinoma patients receiving gemcitabine. ( Alkaff, SMF; Chan, CY; Chan, ECY; Goh, S; Kam, JH; Leow, WQ; Lim, TKH; Phua, LC; Tai, DWM, 2018) |
| "Resistance to gemcitabine remains a key challenge in the treatment of pancreatic ductal adenocarcinoma (PDAC), necessitating the constant search for effective strategies for a priori prediction of clinical outcome." | 3.88 | Metabolomic prediction of treatment outcome in pancreatic ductal adenocarcinoma patients receiving gemcitabine. ( Alkaff, SMF; Chan, CY; Chan, ECY; Goh, S; Kam, JH; Leow, WQ; Lim, TKH; Phua, LC; Tai, DWM, 2018) |
| "Resected pancreatic cancer (n = 21) and normal pancreas were laser-capture micro-dissected, and transcripts were quantified by RNAseq." | 1.48 | Identification of a pyruvate-to-lactate signature in pancreatic intraductal papillary mucinous neoplasms. ( Bamlet, WR; Carlson, SK; Couch, FJ; Damgard, SE; Deelchand, DK; Kittelson, E; Marjańska, M; Murphy, SJ; O'Brien, DR; Passow, MR; Penheiter, AR; Port, JD; Smyrk, TC; Vasmatzis, G, 2018) |
| " In all groups, no adverse effects were noted, and all animals showed favorable local and systemic tolerability." | 1.43 | Preclinical Safety Evaluation in Rats of a Polymeric Matrix Containing an siRNA Drug Used as a Local and Prolonged Delivery System for Pancreatic Cancer Therapy. ( Domb, AJ; Gabai, RM; Marzoli, GA; Muravnik, S; Nyska, A; Ramot, Y; Rotkopf, S; Shemi, A; Zorde Khvalevsky, E, 2016) |
| "The role of CD147 in pancreatic cancer, however, remains elusive." | 1.35 | CD147 silencing inhibits lactate transport and reduces malignant potential of pancreatic cancer cells in in vivo and in vitro models. ( Adler, G; Bucholz, M; Gress, TM; Gschwend, JE; Holzmann, KH; Marx, M; Oswald, F; Scheler, M; Schneiderhan, W; Seufferlein, T, 2009) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (7.69) | 29.6817 |
| 2010's | 10 (76.92) | 24.3611 |
| 2020's | 2 (15.38) | 2.80 |
| Authors | Studies |
|---|---|
| Kitamura, F | 1 |
| Semba, T | 1 |
| Yasuda-Yoshihara, N | 1 |
| Yamada, K | 1 |
| Nishimura, A | 1 |
| Yamasaki, J | 1 |
| Nagano, O | 1 |
| Yasuda, T | 1 |
| Yonemura, A | 1 |
| Tong, Y | 1 |
| Wang, H | 1 |
| Akiyama, T | 1 |
| Matsumura, K | 1 |
| Uemura, N | 1 |
| Itoyama, R | 1 |
| Bu, L | 1 |
| Fu, L | 1 |
| Hu, X | 1 |
| Wei, F | 1 |
| Mima, K | 1 |
| Imai, K | 1 |
| Hayashi, H | 1 |
| Yamashita, YI | 1 |
| Miyamoto, Y | 1 |
| Baba, H | 1 |
| Ishimoto, T | 1 |
| Bhagat, TD | 1 |
| Von Ahrens, D | 1 |
| Dawlaty, M | 1 |
| Zou, Y | 1 |
| Baddour, J | 1 |
| Achreja, A | 1 |
| Zhao, H | 1 |
| Yang, L | 1 |
| Patel, B | 1 |
| Kwak, C | 1 |
| Choudhary, GS | 1 |
| Gordon-Mitchell, S | 1 |
| Aluri, S | 1 |
| Bhattacharyya, S | 1 |
| Sahu, S | 1 |
| Bhagat, P | 1 |
| Yu, Y | 1 |
| Bartenstein, M | 1 |
| Giricz, O | 1 |
| Suzuki, M | 1 |
| Sohal, D | 1 |
| Gupta, S | 1 |
| Guerrero, PA | 1 |
| Batra, S | 1 |
| Goggins, M | 1 |
| Steidl, U | 1 |
| Greally, J | 1 |
| Agarwal, B | 1 |
| Pradhan, K | 1 |
| Banerjee, D | 1 |
| Nagrath, D | 1 |
| Maitra, A | 2 |
| Verma, A | 1 |
| Markovic, S | 1 |
| Roussel, T | 1 |
| Agemy, L | 1 |
| Sasson, K | 1 |
| Preise, D | 1 |
| Scherz, A | 1 |
| Frydman, L | 1 |
| Dovmark, TH | 1 |
| Saccomano, M | 1 |
| Hulikova, A | 1 |
| Alves, F | 1 |
| Swietach, P | 1 |
| Penheiter, AR | 1 |
| Deelchand, DK | 1 |
| Kittelson, E | 1 |
| Damgard, SE | 1 |
| Murphy, SJ | 1 |
| O'Brien, DR | 1 |
| Bamlet, WR | 1 |
| Passow, MR | 1 |
| Smyrk, TC | 1 |
| Couch, FJ | 1 |
| Vasmatzis, G | 1 |
| Port, JD | 1 |
| Marjańska, M | 1 |
| Carlson, SK | 1 |
| Phua, LC | 1 |
| Goh, S | 1 |
| Tai, DWM | 1 |
| Leow, WQ | 1 |
| Alkaff, SMF | 1 |
| Chan, CY | 1 |
| Kam, JH | 1 |
| Lim, TKH | 1 |
| Chan, ECY | 1 |
| Fujioka, R | 1 |
| Mochizuki, N | 1 |
| Ikeda, M | 1 |
| Sato, A | 1 |
| Nomura, S | 1 |
| Owada, S | 1 |
| Yomoda, S | 1 |
| Tsuchihara, K | 1 |
| Kishino, S | 1 |
| Esumi, H | 1 |
| Li, X | 1 |
| Lee, Y | 1 |
| Kang, Y | 2 |
| Dai, B | 1 |
| Perez, MR | 2 |
| Pratt, M | 2 |
| Koay, EJ | 2 |
| Kim, M | 2 |
| Brekken, RA | 1 |
| Fleming, JB | 2 |
| Dutta, P | 1 |
| Lee, J | 1 |
| Salzillo, TC | 1 |
| Weygand, J | 1 |
| Zacharias, NM | 1 |
| Gammon, ST | 1 |
| McAllister, F | 1 |
| Sen, S | 1 |
| Piwnica-Worms, D | 1 |
| Bhattacharya, PK | 1 |
| Guillaumond, F | 1 |
| Leca, J | 1 |
| Olivares, O | 1 |
| Lavaut, MN | 1 |
| Vidal, N | 1 |
| Berthezène, P | 1 |
| Dusetti, NJ | 1 |
| Loncle, C | 1 |
| Calvo, E | 1 |
| Turrini, O | 1 |
| Iovanna, JL | 1 |
| Tomasini, R | 1 |
| Vasseur, S | 1 |
| Longati, P | 1 |
| Jia, X | 1 |
| Eimer, J | 1 |
| Wagman, A | 1 |
| Witt, MR | 1 |
| Rehnmark, S | 1 |
| Verbeke, C | 1 |
| Toftgård, R | 1 |
| Löhr, M | 1 |
| Heuchel, RL | 1 |
| Ramot, Y | 1 |
| Rotkopf, S | 1 |
| Gabai, RM | 1 |
| Zorde Khvalevsky, E | 1 |
| Muravnik, S | 1 |
| Marzoli, GA | 1 |
| Domb, AJ | 1 |
| Shemi, A | 1 |
| Nyska, A | 1 |
| Schneiderhan, W | 1 |
| Scheler, M | 1 |
| Holzmann, KH | 1 |
| Marx, M | 1 |
| Gschwend, JE | 1 |
| Bucholz, M | 1 |
| Gress, TM | 1 |
| Seufferlein, T | 1 |
| Adler, G | 1 |
| Oswald, F | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| An Open-label, Multi-center, Phase 1b Study to Investigate the Safety and Tolerability of SLC-0111 (WBI-5111) in Combination With Gemcitabine in Metastatic Pancreatic Ductal Adenocarcinoma Subjects Positive for Carbonic Anhydrase IX[NCT03450018] | Phase 1/Phase 2 | 30 participants (Anticipated) | Interventional | 2019-01-10 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 trial available for lactic acid and Carcinoma, Pancreatic Ductal
| Article | Year |
|---|---|
Change in plasma lactate concentration during arctigenin administration in a phase I clinical trial in patients with gemcitabine-refractory pancreatic cancer.
Topics: Antineoplastic Agents, Phytogenic; Arctium; Area Under Curve; Biomarkers; Carcinoma, Adenosquamous; | 2018 |
12 other studies available for lactic acid and Carcinoma, Pancreatic Ductal
| Article | Year |
|---|---|
Cancer-associated fibroblasts reuse cancer-derived lactate to maintain a fibrotic and immunosuppressive microenvironment in pancreatic cancer.
Topics: Animals; Cancer-Associated Fibroblasts; Carcinoma, Pancreatic Ductal; Glucose; Humans; Lactic Acid; | 2023 |
Lactate-mediated epigenetic reprogramming regulates formation of human pancreatic cancer-associated fibroblasts.
Topics: 5-Methylcytosine; Animals; Cancer-Associated Fibroblasts; Carcinoma, Pancreatic Ductal; Cell Line, T | 2019 |
Deuterium MRSI characterizations of glucose metabolism in orthotopic pancreatic cancer mouse models.
Topics: Adenocarcinoma; Animals; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Deuterium; Disease Models, | 2021 |
Connexin-43 channels are a pathway for discharging lactate from glycolytic pancreatic ductal adenocarcinoma cells.
Topics: Acidosis, Lactic; Animals; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Connexin 43; Gap Junction | 2017 |
Identification of a pyruvate-to-lactate signature in pancreatic intraductal papillary mucinous neoplasms.
Topics: Adenocarcinoma, Mucinous; Biomarkers, Tumor; Carcinoma, Pancreatic Ductal; Carcinoma, Papillary; Gen | 2018 |
Metabolomic prediction of treatment outcome in pancreatic ductal adenocarcinoma patients receiving gemcitabine.
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Biomarkers; Carcinoma, Pancreatic Ductal; Deo | 2018 |
Hypoxia-induced autophagy of stellate cells inhibits expression and secretion of lumican into microenvironment of pancreatic ductal adenocarcinoma.
Topics: AMP-Activated Protein Kinases; Animals; Autophagy; Carcinoma, Pancreatic Ductal; Cell Hypoxia; Cell | 2019 |
Combining Hyperpolarized Real-Time Metabolic Imaging and NMR Spectroscopy To Identify Metabolic Biomarkers in Pancreatic Cancer.
Topics: Animals; Biomarkers, Tumor; Carcinoma, Pancreatic Ductal; Glycolysis; Heterografts; Humans; Hypoxia- | 2019 |
Strengthened glycolysis under hypoxia supports tumor symbiosis and hexosamine biosynthesis in pancreatic adenocarcinoma.
Topics: Animals; Carcinoma, Pancreatic Ductal; Cell Hypoxia; Cell Line, Tumor; Cell Survival; Disease Models | 2013 |
3D pancreatic carcinoma spheroids induce a matrix-rich, chemoresistant phenotype offering a better model for drug testing.
Topics: Animals; Antineoplastic Agents; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Disease Models, Anim | 2013 |
Preclinical Safety Evaluation in Rats of a Polymeric Matrix Containing an siRNA Drug Used as a Local and Prolonged Delivery System for Pancreatic Cancer Therapy.
Topics: Animals; Antineoplastic Agents; Carcinoma, Pancreatic Ductal; Drug Carriers; Lactic Acid; Pancreatic | 2016 |
CD147 silencing inhibits lactate transport and reduces malignant potential of pancreatic cancer cells in in vivo and in vitro models.
Topics: Animals; Basigin; Blotting, Western; Carcinoma, Pancreatic Ductal; Chick Embryo; Dose-Response Relat | 2009 |